Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP) -- Ignore unavailable to you. Want to Upgrade?

To: David Culver who wrote (1184)	2/10/1999 10:15:00 PM
From: Harold Lehman	Read Replies (1) \| Respond to of 1501

I also asked Jeff Bacha about the tb antigen test as well. As you know it's licensed to Cortecs Pharmaceuticals, which had management changes at the highest levels late last year. Inflazyme has been in frequent contact with them to ascertain whether the continued development of this test is still a high-priority item with them. When I asked whether this test, which has had a lot of developmental work by Cortecs, could revert back to Inflazyme, I was told that they hope to get an answer soon from Cortecs, and then they'll see. I had the distinct impression that it could revert back to IZP if it's not high priority with Cortecs. That, in my opinion, would be good, as a lot of work has been put into it already, and I believe it has a very large, if not huge, market. Harold

To: David Culver who wrote (1184)	2/10/1999 10:17:00 PM
From: Rob	Respond to of 1501

No sooner did I post my last message then I read the news on Entremed, the tumor anti-angiogenesis company that made the front page of the New York Times several months ago with their rocket-like ascent. The bottom fell out today (~50% loss) when their "partner" Bristol-Myers pulled the plug. Take a visit to their board (ENMD), I think it illustrates why I feel cautious optimism is always in order. You might want to bring a First Aid kit, it's not pretty over there. P.S. My guess is this will prove to be a short-lived decline once his highly fastidious methods are reproduced independently. Rob